GENOIMMUNE THERAPEUTICS CO LTD has a total of 16 patent applications. Its first patent ever was published in 2016. It filed its patents most often in WIPO (World Intellectual Property Organization), China and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLOGICA DE VALL HEBRON, LEE JONG Y and ONCOLOGIE INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | China | 5 | |
#3 | United States | 5 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Computer technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Healthcare informatics |
# | Name | Total Patents |
---|---|---|
#1 | Li Bo | 16 |
#2 | Hou Yong | 16 |
#3 | Luo Shuntao | 15 |
#4 | An Ting | 15 |
#5 | Lin Xiumei | 15 |
#6 | Chao Chengchi | 6 |
#7 | Li Handong | 6 |
#8 | Yang Naibo | 6 |
#9 | Li Guanglei | 6 |
#10 | Cheng Zhen | 6 |
Publication | Filing date | Title |
---|---|---|
WO2021031113A1 | Anti-bcma antibody and use thereof in car-t field | |
US2020024316A1 | Cacna1h-derived tumor antigen polypeptide and use thereof | |
US2019224291A1 | Col14a1-derived tumor antigen polypeptide and use thereof | |
WO2018045510A1 | Polypeptide and application thereof | |
CN109803978A | Polypeptide and its application | |
WO2018032501A1 | Novel tumor-specific polypeptide and application thereof |